Relmada Therapeutics (RLMD) Earnings Date & Reports

Key Takeaways

• Relmada reported a net loss of $13.9 million, or $0.12 per share, for the third quarter ended September 30, 2026, beating the consensus estimate of a $0.14 loss per share.
• The per-share loss narrowed significantly from $0.30 a year earlier, helped by a larger share count following recent capital raises.
• Research and development (R&D) expense more than doubled to $9.2 million from $4.0 million, reflecting heavier investment in the NDV-01 and sepranolone programs.
• Cash, cash equivalents, and short-term investments totaled $202.1 million as of September 30, 2026, up from $93.0 million at the end of 2025.
• Updated 18-month Phase 2 data for lead candidate NDV-01 showed 86% of evaluable patients remained in complete response in non-muscle invasive bladder cancer (NMIBC).
• The Phase 3 registrational program has been renamed SPECTRUM, with an Investigational New Drug (IND) application submission expected by year-end 2026.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• You can also discover fresh opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Relmada Therapeutics is a clinical-stage biotechnology company with no product revenue, so its quarterly results are less about sales and more about cash runway, spending discipline, and clinical progress. Investors watch these reports primarily for pipeline updates, because the company's value hinges on the success of NDV-01, an intravesical therapy for non-muscle invasive bladder cancer, and sepranolone, a candidate for central nervous system disorders. Following a 2025 capital raise, Relmada has extended its funding runway while accelerating development spending. This quarter's report carried added weight because it delivered the first 18-month durability data from the Phase 2 NDV-01 study, a key signal of whether the therapy can produce lasting responses.

Reported Results

For the third quarter of 2026, Relmada posted a net loss of $13.9 million, or $0.12 per basic and diluted share, compared with a net loss of $10.1 million, or $0.30 per share, in the prior-year period. The narrower per-share loss beat the consensus estimate of roughly $0.14 and reflected a higher share count rather than lower absolute spending. Revenue remained at zero, consistent with the company's clinical-stage status.

R&D expense rose to $9.2 million from $4.0 million a year ago as the company advanced manufacturing and development for NDV-01 and sepranolone. On the balance sheet, cash, cash equivalents, and short-term investments stood at approximately $202.1 million as of September 30, 2026, up from $93.0 million at December 31, 2025, providing a multi-year runway.

The highlight of the update was clinical rather than financial. Updated 18-month results from the ongoing Phase 2 study of NDV-01 showed that 12 of 14 evaluable patients (86%) remained in complete response, including 7 of 8 patients (88%) in the BCG-unresponsive subgroup. No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations were reported. The company also confirmed it expects to submit its IND application for NDV-01 by year-end 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring a clinical-stage name like RLMD, it offers a structured way to track momentum and peer activity as pipeline catalysts unfold.

Market Reaction and Investor Sentiment

Sentiment around RLMD has been shaped more by clinical milestones than by headline financials. The narrower-than-expected loss and strengthened cash position were welcome, but the 18-month durability data from the NDV-01 Phase 2 study was the primary focus. Investors interpreted the sustained complete response rates and clean safety profile as supportive of the drug's profile in NMIBC, where durable, bladder-sparing options remain limited.

Key risks heading into and following this report include manufacturing and chemistry, manufacturing, and controls (CMC) execution, the timing of IND clearances, and the inherent uncertainty of Phase 3 outcomes. As a development-stage biotech, Relmada's shares have historically been volatile around data and regulatory announcements, and investors will likely remain focused on execution milestones through the end of 2026.

Forward Outlook and Key Factors to Monitor

Relmada's near-term narrative now centers on regulatory and clinical execution. The company expects to submit an IND application for NDV-01 by year-end 2026, which would clear the path to initiate the Phase 3 SPECTRUM program across two FDA-aligned registrational pathways. Investors will watch closely for confirmation of that submission and any feedback from regulators.

In parallel, the company is preparing a separate IND submission for sepranolone, its candidate for Prader-Willi syndrome, also targeted for year-end 2026, with a Phase 2 proof-of-concept study expected to begin upon IND clearance. Manufacturing readiness will be another important factor, since the company has emphasized building uninterrupted clinical supply through Phase 3 and supporting commercial readiness.

Finally, spending trends and cash runway remain central for a pre-revenue biotech. With roughly $202.1 million on hand, Relmada has extended its operating runway, but investors will monitor how quickly R&D expenses accelerate as multiple programs move toward late-stage trials. The balance between advancing the pipeline and preserving capital will be a recurring theme in coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations